Last $1.05 USD
Change Today +0.01 / 0.96%
Volume 49.8K
VICL On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 2:01 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

vical inc (VICL) Snapshot

Open
$1.03
Previous Close
$1.04
Day High
$1.05
Day Low
$1.03
52 Week High
02/12/14 - $1.66
52 Week Low
12/16/14 - $0.89
Market Cap
94.8M
Average Volume 10 Days
236.9K
EPS TTM
$-0.17
Shares Outstanding
90.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VICAL INC (VICL)

vical inc (VICL) Related Bloomberg News

View More Bloomberg News

vical inc (VICL) Related Businessweek News

No Related Businessweek News Found

vical inc (VICL) Details

Vical Incorporated is engaged in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Its product candidates include CyMVectin prophylactic vaccine for cytomegalovirus (CMV), which completed preclinical trial to prevent infection before pregnancy to preclude fetal transmission; and therapeutic and prophylactic vaccines for herpes simplex virus type 2, which are under Phase 1/2 clinical trial to prevent and protect against recurring flare-ups, reduce viral shedding, and transmission. The company, through corporate collaborations, is also developing TransVax, which is in Phase III clinical trial to protect against CMV infection after stem cell transplants, as well as in Phase II clinical trial for prevention of CMV infection in kidney transplant recipients; and ONCEPT therapeutic cancer vaccine encoding human tyrosinase for the treatment to enhance survival time of dogs with oral melanoma. In addition, Vical Incorporated, through government collaboration, is developing Tetravalent dengue vaccine, a Phase I clinical trial product to prevent dengue disease caused by all four dengue serotypes. Further, it is also engaged in contract manufacturing of plasmid investigational products for various clients. The company was founded in 1987 and is headquartered in San Diego, California.

67 Employees
Last Reported Date: 02/14/14
Founded in 1987

vical inc (VICL) Top Compensated Officers

Chief Executive Officer, President, Acting Ch...
Total Annual Compensation: $557.0K
Chief Accounting Officer and Vice President o...
Total Annual Compensation: $229.2K
Senior Vice President of Corporate Developmen...
Total Annual Compensation: $271.8K
Vice President of Vaccine Research
Total Annual Compensation: $267.8K
Compensation as of Fiscal Year 2013.

vical inc (VICL) Key Developments

Vical Incorporated and AnGes MG Enter into Collaboration to Develop and Commercialize an Equine Polyclonal Antibody Therapy for Patients Afflicted with Ebola Virus Disease

Vical Incorporated and AnGes MG announced that they have entered into collaboration to develop and commercialize an equine polyclonal antibody therapy for patients afflicted with Ebola virus disease. No medicines or vaccines are currently approved for the treatment of Ebola. Unlike prophylactic vaccines, which require widespread vaccinations, multiple doses and time in order to mount a protective immune response prior to exposure, polyclonal antibody therapy offers a more targeted approach of providing immediate immune globulin as a treatment against Ebola virus. Therapeutic approaches utilizing equine polyclonal antibodies have been used for the treatment of viral diseases such as rabies, bacterial toxins such as tetanus and diphtheria, as well as black widow spider venom. The planned approach will be to isolate antibodies from the horses immunized with a DNA vaccine encoding an Ebola virus glycoprotein antigen. The antibodies will be purified and developed for the treatment of Ebola virus disease in humans. Under the agreement, Vical will develop and provide to AnGes a DNA vaccine encoding the glycoprotein antigen of the 2014 Zaire strain of Ebola virus, formulated with Vical's proprietary Vaxfectin® adjuvant. AnGes will receive the right to exclusively develop and commercialize the equine polyclonal antibody therapy in Japan and will be responsible for all development costs. Vical will receive an upfront payment and is eligible to receive royalties on net sales and a percentage of payments received by AnGes under any sub-licensing agreements.

Vical Completes Enrollment in its Therapeutic HSV-2 Vaccine Clinical Trial

Vical Incorporated announced the completion of enrollment in a Phase 1/2 trial of its Vaxfectin-formulated therapeutic vaccine for herpes simplex virus type 2 (HSV-2), the predominant cause of recurrent genital herpes. The enrollment was completed on schedule as originally planned. The randomized, double-blind, placebo-controlled trial will evaluate safety, tolerability and efficacy of two vaccine candidates (one encoding glycoprotein D alone and the other in combination with UL46). The study is powered to show at least a 30% decrease in the viral shedding rate following 3 doses of vaccine. A total of 165 otherwise healthy HSV-2- infected patients aged 18 to 50 years were enrolled across seven U.S. trial sites. The Company expects to release efficacy data by the middle of 2015. HSV-2 is a sexually transmitted virus which is the leading cause of recurrent genital herpes. Approximately one out of every six individuals aged 15 to 49 years worldwide is chronically infected with HSV-2. HSV-2 infections are persistent and can result in genital lesions, as well as periodic virus shedding placing sexual partners at risk of infection. The presence of HSV-2 genital lesions also significantly increases the risk of acquiring HIV-1 from HIV-infected sexual partners. There is no FDA approved vaccine for HSV-2.

Vical Incorporated Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 01:30 PM

Vical Incorporated Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 01:30 PM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VICL:US $1.05 USD +0.01

VICL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Dynavax Technologies Corp $17.20 USD +0.10
Genocea Biosciences Inc $8.71 USD +0.1201
GenVec Inc $3.38 USD +0.09
Inovio Pharmaceuticals Inc $8.34 USD -0.1601
Peregrine Pharmaceuticals Inc $1.30 USD -0.02
View Industry Companies
 

Industry Analysis

VICL

Industry Average

Valuation VICL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.9x
Price/Book 1.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VICAL INC, please visit www.vical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.